Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Blumenstein, I. [1 ]
Xuan, S. [2 ]
Panaccione, R. [3 ]
Baert, F. [4 ]
Barreiro-de Acosta, M. [5 ]
Ye, B. D. [6 ,7 ]
Klaff, J. [2 ]
Vladea, R. [2 ]
Levy, G. [2 ]
Holweg, C. T. J. [2 ]
Gonzalez, Y. Sanchez [2 ]
Dubinsky, M. C. [8 ]
机构：
[1] Goethe Univ Clin, Frankfurt, Germany
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Calgary, Dept Gastroenterol & Hepatol, Calgary, AB, Canada
[4] AZ Delta, Dept Gastroenterol, Roeselare, Belgium
[5] Univ Hosp Santiago de Compostela, Inflammatory Bowel Dis Unit, Galicia, Spain
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Gastroenterol, Seoul, South Korea
[7] Univ Ulsan, Inflammatory Bowel Dis Ctr, Seoul, South Korea
[8] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein IBD Ctr, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P179
引用
收藏
页码：I333 / I334
页数：2
相关论文
共 50 条
  • [31] Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
    Fung, Simon
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, : 433 - 443
  • [32] EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Klaff, Justin
    Ilo, Dapo
    Yao, Xuan
    Levy, Gweneth
    Higgins, Peter D.
    Loftus, Edward V.
    Panaccione, Remo
    GASTROENTEROLOGY, 2022, 162 (07) : S227 - S228
  • [33] Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
    Vermeire, S.
    Danese, S.
    Zhou, W.
    Klaff, J.
    Ilo, D.
    Yao, X.
    Levy, G.
    Higgins, P. D. R.
    Loftus-, E. V., Jr.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I090 - I091
  • [34] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
    Ignacio Fernandez-Blanco, J.
    Fernandez-Diaz, Guillermo
    Cara, Carlos
    Vera, Maria I.
    Olivares, David
    Taxonera, Carlos
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) : 731 - 737
  • [35] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Lazar, Andreas
    GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115
  • [36] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
    J. Ignacio Fernández-Blanco
    Guillermo Fernández-Díaz
    Carlos Cara
    María I. Vera
    David Olivares
    Carlos Taxonera
    Digestive Diseases and Sciences, 2018, 63 : 731 - 737
  • [37] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [38] Etrolizumab as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis: a protocol of systematic review and meta-analysis of placebo-controlled, randomised clinical trials
    Qin, Xuan
    Wang, Menghui
    Zhang, Wei
    Liu, Wenji
    Shu, Hongxin
    Xiong, Xiaowei
    BMJ OPEN, 2024, 14 (01):
  • [39] Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Ilo, Dapo
    Klaff, Justin
    Levy, Gweneth
    Yao, Xuan
    Chen, Su
    Gonzalez, Yuri Sanchez
    Hebuterne, Xavier
    Lindsay, James
    Higgins, Peter D. R.
    Cao, Qian
    Nakase, Hiroshi
    Colombel, Jean-Frederic
    Loftus, Edward V., Jr.
    Panaccione, Remo
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 976 - 989
  • [40] Efficacy of Induction upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn's Disease
    Chen, M.
    Gao, X.
    Cao, Q.
    Zhang, X.
    Chen, Y.
    Hou, X.
    Zhong, J.
    Sun, Y.
    Phaleng, X.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1213 - I1213
12345